May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
WaveLight Allegretto Eye-Q 400 Hz Laser Performance in EpiLASIK
Author Affiliations & Notes
  • A. E. Ahuero
    Ophthalmology, Harvard Medical School MEEI, Boston, Massachusetts
  • P. Gupta
    Ophthalmology, Harvard Medical School MEEI, Boston, Massachusetts
  • T. Tanhehco
    Ophthalmology, Harvard Medical School MEEI, Boston, Massachusetts
  • U. Jurkunas
    Ophthalmology, Harvard Medical School MEEI, Boston, Massachusetts
  • R. Pineda, II
    Ophthalmology, Harvard Medical School MEEI, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  A.E. Ahuero, None; P. Gupta, None; T. Tanhehco, None; U. Jurkunas, None; R. Pineda, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3352. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. E. Ahuero, P. Gupta, T. Tanhehco, U. Jurkunas, R. Pineda, II; WaveLight Allegretto Eye-Q 400 Hz Laser Performance in EpiLASIK. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3352. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the results of epithelial laser-in situ keratomileusis (EpiLASIK) performed with the WaveLight Allegretto Eye-Q 400 Hz laser at a single-site academic center.

Methods: : We performed a retrospective chart review of all patients undergoing EpiLASIK with the EpiTome (Gebauer Co., Germany) starting from October 13, 2006. We analyzed the spherical equivalent, uncorrected visual acuity (UCVA), and rate of enhancement of the first 34 eyes. Complications of the procedure were recorded. Exclusion criteria included follow-up data less than 3 months.

Results: : The Allegretto laser was used to perform EpiLASIK on 15 patients, 28 eyes, between 10/13/2006 and 8/17/2007. Range of spherical correction includes eyes from +1.00 diopters (D) to - 7.00 D. Cylindrical correction was from 0.00 D to -1.50 D. At 3 month follow-up 15 of 16 eyes (93.8%) were within +/- 0.50 D of aimed correction. Out of all patients that were aimed to be plano, at 6 months 11 of 12 eyes (91.7%) achieved UCVA of at least 20/20. None of the patients required enhancement. No complications were found in any case.

Conclusions: : The Allegretto laser platform provides excellent results when combined with EpiLASIK requiring no need for enhancement for our cases. Further cases will be necessary to provide more data on the enhancement and complication rates associated with this laser platform combined with EpiLASIK.

Keywords: refractive surgery: other technologies • cornea: clinical science • refractive surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×